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The feasibility of using activity-directed synthesis to drive antibac-
terial discovery was investigated. An array of 220 Pd-catalysed
microscale reactions was executed, and the crude product mixtures
were evaluated for activity against Staphylococcus aureus. Scale-up
of the hit reactions, purification and evaluation, enabled expansion
of a class of antibacterial quinazolinones. The novel antibacterials
had MICs from 0.016 lg mL1 (i.e. 38 nM) to 2–4 lg mL1 against
S. aureus ATCC29213.
The discovery of bioactive small molecules is generally driven
through iterative design-make-purify-test cycles. The process is
generally underpinned by a remarkably narrow toolkit1 of
reliable reaction classes which limits the diversity of explored
chemical space.2 We have recently introduced activity-directed
synthesis3 (ADS), a structure-blind and function-driven discov-
ery approach. In ADS, inherently promiscuous chemistry is har-
nessed in which arrays of reactions are performed, and each
reaction has multiple possible outcomes. The crude reaction
mixtures are then directly screened for biological activity. We
have previously harnessed metal carbenoid chemistry to drive the
activity-directed discovery of diverse series of androgen receptor
agonists and protein–protein interaction inhibitors.3
Here, we demonstrate the generality of ADS by showing that
other reaction classes (here, Pd-catalysed carbonylation4) and
assay types (here, whole-cell antibacterial activity against the
ESKAPE5 pathogen S. aureus) may be harnessed. We show that
the approach may be used to expand a series of quinazolinones6
that was developed to target penicillin-binding proteins, and
displays promising activity (minimum inhibitory concentrations
[MICs] as low as 0.003 mg mL1) against multiple strains of
S. aureus.6a
We envisaged that Pd-catalysed reactions may complement
the metal carbenoid chemistry that we have previously har-
nessed in ADS (Fig. 1). Specifically, we noted its potential to
yield alternative scaffolds from a common substrate (such as 1).
For example, Pd-catalysed carbonylation, followed by reaction
with an amine and cyclisation, could yield 2,3-disubstituted
quinazolinones such as 2. Alternatively, Pd-catalysed amina-
tion, without carbonylation, could yield anilines (e.g. 3) or, with
subsequent cyclisation, benzimidazoles (e.g. 4). Finally, intra-
molecular Heck reaction could yield quinolinones (e.g. 5).
Initially, we adapted a Pd-catalysed carbonylation reaction7
for execution on a 300 ml scale (100 mmol substrate) in micro-
scale vials in 96-well plate format (Scheme 1). Accordingly, the
o-iodo anilide 6a (final concentration: 333 mM), the aniline
(1.2 eq.), Mo(CO)6 (1 eq.), Pd2(dba)3 (0.1 mol%), P(
tBu3)HBF4
(0.6 mol%) and NEt3 (2.5 eq.) were dissolved in o-xylene; after
Fig. 1 Potential of Pd-catalysed chemistry to yield alternative scaffolds
from common substrates (such as 1), amines and, in some cases, a carbon
monoxide source. Groups derived from an amine co-substrate (blue) and
carbon monoxide (red) are indicated.
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sealing, the vial was heated at 105 1C for 48 h. It was shown that
the yield of 8a, determined by NMR spectroscopy using an internal
standard, was broadly similar to that obtained on a preparative
scale in a crimp-top vial. At this stage, the quinazolinones 8b and
8c6a were also prepared. Crucially, we had shown that Pd-catalysed
chemistry was viable in a format suitable for ADS, and that stirring
and an inert atmosphere were not necessary.
We adapted standard susceptibility testing methodology8 to
assess antibacterial activity against S. aureus ATCC29213. Quina-
zolinone solubility was improved by using Iso-Sensitest Broth
(ISB)9 as the growth medium, and MICs were determined for
8b–c [8b: 0.5–1 mg mL1 (1.45–2.90 mM); 8c: 0.125–0.25 mg mL1
(0.34–0.68 mM)]. The reaction of 6b and 7b (which would yield the
antibacterial 8b) was then repeated in a microscale vial, the
reaction filtered through silica, evaporated, and the crude reaction
mixture dissolved in DMSO (total product concentration: 333 mM).
The stock solution of the crude product was screened at multiple
total product concentrations (100 mM, 50 mM, 25 mM and 10 mM;
entries 1 and 9–11, Table 1): visual growth inhibition was only
detected at the two highest concentrations. Crucially, the reaction
of 6a and 7b did not yield an active crude product at 50 mM total
product concentration (entry 2). In addition, the reactions of the
individual reactants 6a, 6b and 7b (entries 3–5), as well as the
individual components P(tBu3)HBF4, Mo(CO)6 and Pd2(dba)3
(entries 6–8), also did not result in detectable activity. The assay
was deemed suitable for activity-directed antibacterial discovery
since activity was only observed for reactions that could have
yielded the positive control 8b.
Having established appropriate synthetic and biological meth-
ods for ADS, we designed a reaction array based on ten substrates
S1–S10 (and no substrate) and nineteen co-substrates C1–C19
(and no co-substrate). The array of 220 reactions was designed to
enable formation of a diverse range of quinazolinones, some
related to known analogues,6 as well as other products of Pd-
catalysed processes. The substrates were mainly analogues of S1
(e.g. dehomologated, constrained), whilst the aniline and amine
co-substrates bore structurally-diverse aryl, hetaryl and other
substituents. To expand the possible reaction outcomes, some
substrates and co-substrates bore alternative (e.g. S2 and S9) or
additional (e.g. C6, C12 and C16) nucleophiles. The substrates and
co-substrates were all inactive against S. aureus ATCC29213 at
50 mM. The array was performed in a 96-well OptiBlock and
assembled from stock solutions using multi-channel pipettes.
After 48 h at 105 1C, the crude reaction mixtures were filtered
through silica, evaporated and dissolved in DMSO (total product
concentration: 333 mM). Randomly-selected product mixtures
(n = 23) were analysed by LC/MS; 16 of these contained carbonyl-
ated intermolecular products, 13 of which had been dehydrated.
In addition, one product mixture (S3 + C1) contained the product
of an intramolecular reaction of S3, later shown to stem from a
reductive Heck reaction10 (see ESI†).
The crude reactionmixtures were screened in duplicate against
S. aureus ATCC29213 (final total product concentration of 50 mM
in 1% DMSO in ISB) (Fig. 2). Six of the 220 reactions displayed
significant antibacterial activity in both replicate cultures: sub-
strate S1 (with C1 or C18); substrate S7 (with C18); and substrate
S10 (with C1, C6 or C18). Reassuringly, the combination of S1 and
C1 had been previously validated in our method development
work (Table 1). The remaining five hit reactions were scaled fifty-
fold, and the products purified by mass-directed HPLC (Table 2).
In each case, quinazolinones with an extended hydrophobic
substituent in the 2-position, and ameta-substituted phenyl group
in the 3-position, were obtained. The products had MIC values
Scheme 1 Configuration of Pd-catalysed chemistry for use in ADS. aLC-MS
analysis of the reaction performed in a microscale vial revealed that the product
had been formed successfully. bPrepared using a precedented method (ref. 6a).
Table 1 Configuration of antibacterial assay to be suitable for ADS
Entrya Substrate Co-Substrateb Reagentsc Conc.d/mM Activitye
1 6b 7b All 50
2 6a 7b All 50
3 6b — All 50
4 6a — All 50
5 — 7b All 50
6 — — P(tBu3)HBF4 50
7 — — Mo(CO)6 50
8 — — Pd2(dba)3 50
9 6b 7b All 100
10 6b 7b All 25
11 6b 7b All 10
a Reactions performed in microscale vials at 105 1C; crude reaction
mixtures were filtered through silica, evaporated and dissolved in DMSO
(total product concentration: 333mM) before evaluation. b 1.2 eq. c Mo(CO)6
(1 eq.), 0.1 mol% Pd2dba3, 0.6 mol% P(
tBu3)HBF4, NEt3 (2.5 eq.), o-xylene.
d Total product concentration based on limiting substrate. e Activity against
S. aureus ATCC29213 (see Fig. 2 for colour scale); a tick indicates visual growth
inhibition (see ESI). f LC-MS revealed that a quinazolinone had been formed.
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against S. aureus ATCC29213 ranging from 0.016 mg mL1 (i.e.
38 nM) for 8d to 2–4 mgmL1 (i.e. 6–12 mM) for 8g. Notably, 8dwas
B10-fold more active than the positive control6a 8c. The products
8d–h had comparable activity against the methicillin-resistant
USA300 JE2 strain, but were significantly less active against
laboratory strain SH1000. In addition, we purified the products
of three reactions that were not identified as hits: S7 + C1; S7 +
aniline; and S4 + C9; two of these reactions also yielded quinazo-
linones, and the third an uncyclised amide 9, and, crucially, all of
these products displayed significantly lower (or no detectable)
antibacterial activity.
Our experiments enabled the SAR of the quinazolinones to be
significantly expanded (Fig. 3).6 We found that a –CH2CH2– linker
(as in 8d and 8f–h) could be replaced by a trans-disubstituted
cyclopropane (as in 8e); however, reactions involving dehomolo-
gated (e.g. S6) or truncated (e.g. S4) substrates, or those offering
alternative reaction pathways (e.g. S2, S3, S5, S8 and S9), did not
yield antibacterial products. In some cases, themeta OH or NHMs
group (in 8f and 8h) could be replaced by a NH2 group (in 8g);
however, none of the co-substrates that lacked such am-substituted
phenyl group ever yielded antibacterial products. Crucially, the
products of reactions that had not been identified as hits were
substantially less (or not) active. Although the quinazolinone 8i is
matched pair of 8a, 8e and 8h (MICs: 0.5–2 mg mL1), it is
significantly less active (MIC: 4–8 mg mL1). The quinazolinones
8j and the amide 9 were not active, even at 128 mg mL1.
In conclusion, we have shown that ADS is feasible with a
novel reaction class (Pd-catalysed chemistry) and with a phe-
notypic assay (rather than, as previously,3 a biophysical assays).
An array of 220 reactions enabled efficient exploration of the
function of products based on several alternative product
scaffolds. Based on our analysis of reaction outcomes by LC-
MS, and the range of substrates used, we estimate that most of
these reactions productively yielded previously unexplored
Fig. 2 Activity-directed antibacterial discovery (see Table 1 for reaction conditions). Panels A and B: Structures of substrates (A) and co-substrates (B).
Panel C: Activity against S. aureus ATCC29213 (total product concentration: 50 mM), with active combinations that were scaled up shown (yellow).
Product mixtures that displayed activity against only one colony (pink) were re-assayed, but none of these combinations were validated as hits (see ESI†).
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products. Scale-up of the identified hit reactions, and purifica-
tion, yielded a range of antibacterial quinazolinones and,
thereby, expansion of their SAR. We envisage that, by harness-
ing alternative reaction classes to explore diverse chemical
space, ADS may be exploited in the discovery of novel series of
antimicrobials not subject to existing antibiotic resistance
mechanisms.11
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Hit? Substrates Producta (yieldb)
MIC (mg mL1)
ATCC29213 USA300 JE2 SH1000
| S1, C1 8b (19%) 0.5–1 0.5 4
| S1, C18 8d (4%) 0.016 0.016 0.5–1
| S7, C18 8e (2%) 1–2 2 32–64
| S10, C1 8f (8%) 1 0.5–1 4–8
| S10, C6 8g (8%) 2–4 2–4 16
| S10, C18 8h (14%) 0.5 0.5 1–2
‘ S7, C1 8i (21%) 4–8 4–8 16
‘ S4, C9 9 (5%) 4128 64 32–64
‘ S7, aniline 8j (18%) 4128 4128 4128
a Co-Substrate (1.2 eq.), Mo(CO)6 (1 eq.), 0.1 mol% Pd2bda3, 0.6 mol% P(
tBu3)HBF4, NEt3, o-xylene. b After mass-directed HPLC. All compounds
were also screened against yeast (Candida albicans, Ca6) and were found to be inactive at 16 mg mL1.
Fig. 3 SAR expanded using ADS.
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